首页> 外文期刊>Journal of smooth muscle research = >Effect of Fenspiride on Bronchial Smooth Muscle of Rats with Chronic Obstructive Pulmonary Disease
【24h】

Effect of Fenspiride on Bronchial Smooth Muscle of Rats with Chronic Obstructive Pulmonary Disease

机译:灭螺灵对慢性阻塞性肺疾病大鼠支气管平滑肌的影响

获取原文
           

摘要

Chronic obstructive pulmonary disease (COPD) is among the leading causes of morbidity and mortality worldwide. Glucocorticoids are currently the most applicable anti-inflammatory treatment for COPD. However, a subset of COPD subjects is relatively insensitive to this treatment. Fenspiride, a non-corticosteroid anti-inflammatory drug, has been described to have beneficial effects in patients with COPD, although the mechanism of its action is not well known. The effect of fenspiride on contractile activity of bronchial smooth muscle was studied in a rat model of COPD induced by long-term exposure of the animals to nitrogen dioxide (NO2). Contractile activity of bronchial smooth muscle was evaluated in vitro . Isometric contraction of bronchial preparations was measured following electrical stimulation. Fenspiride administration to rats during the acute stage of COPD (15 days of NO2 exposure) prevented the bronchial constriction induced by NO2. The bronchodilator effect of a low-dose of fenspiride (0.15 mg/kg) was mediated by interaction with the nerve endings of capsaicin-sensitive C-fibers. Interaction of fenspiride with C-fibers was shown to prevent initiation of neurogenic inflammation, as evidenced by lack of COPD-like structural changes in the lungs. The bronchodilator effect of a high-dose of fenspiride (15 mg/kg) was mediated not only by the afferent component, but also involved a direct relaxing effect on smooth muscle cells. The anti-inflammatory and bronchodilator effects of a low-dose of fenspiride may be used for prevention of COPD development in individuals from high-risk cohorts exposed to aggressive environmental factors.
机译:慢性阻塞性肺疾病(COPD)是全球发病率和死亡率的主要原因之一。糖皮质激素是目前最适用于COPD的抗炎治疗方法。然而,一部分COPD受试者对该治疗相对不敏感。芬斯必利是一种非皮质类固醇抗炎药,尽管其作用机理尚不清楚,但已被描述对COPD患者具有有益作用。在长期暴露于二氧化氮(NO 2 )诱导的COPD大鼠模型中,研究了杀螺菌肽对支气管平滑肌收缩活性的影响。评估支气管平滑肌的收缩活动。电刺激后测量支气管制剂的等轴测收缩。在COPD急性期(暴露NO 2 15天)对大鼠施用芬斯必利,可预防NO 2 引起的支气管收缩。低剂量的芬斯匹德(0.15 mg / kg)的支气管扩张作用是通过与辣椒素敏感的C纤维的神经末梢相互作用而介导的。如肺中缺乏COPD样结构变化所证明的那样,非那雄胺与C纤维的相互作用可防止神经源性炎症的发生。高剂量的芬斯匹德(15 mg / kg)的支气管扩张药作用不仅由传入成分介导,而且还包括对平滑肌细胞的直接松弛作用。低剂量的芬美利特的抗炎和支气管扩张剂作用可用于预防高危人群的侵袭性环境因素所致的COPD发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号